Indol-3-yl-corbonyl-piperidin-benzoimidazol derivatives

A compound of formula (I-b):

• R1 is H,
• C1-6-alkyl optionally substituted by CN,
• or is aryl, 5 or 6 membered heteroaryl or sulfonylaryl each of which is optionally substituted by one or more B,
• or is —(CH2)m—Ra wherein Ra is:
• CN,
• ORi,
• NRiRii, or
• C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
• or —(CH2)n—(CO)—Rb or —(CH2)n—(SO2)—Rb, wherein Rb is:
• C1-6-alkoxy,
• C3-6-cycloalkyl,
• —(CH2)m—NRiiiRiv,
• NRiRii, or
• C3-6-cycloalkyl, 4 to 7 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B,
• or R1 and R3 together with the indole ring to which they are attached form a 5 or 6 membered heterocycloalkyl which is optionally substituted by ═O;
• there is one or more R2, wherein each R2 is the same or different,
• R2 is one or more H, OH, halo, CN, nitro, C1-6-alkyl optionally substituted by —NRiiiRiv, C1-6-alkoxy, —O—CH2—C2-6-alkenyl, or benzyloxy,
• or two R2 together with the indole ring to which they are attached form an oxo or dioxo bridge;
• R3 is H,
• halo,
• —(CO)—Rc, wherein Rc is:
• C1-6-alkyl,
• —(CH2)n—NRiRii,
• —(CH2)n—NRiiiRiv or
• 5 or 6 membered heterocycloalkyl optionally substituted by C1-6-alkyl, or C1-6-alkyl or aryl, each of which is optionally substituted by
• halo,
• —O(CO)—C1-6-alkyl, or
• —NH(CO)Rd, wherein Rd is C1-6-alkyl optionally substituted by halo or nitro, or Rd is aryl or a 5 or 6 membered heteroaryl, each of which is optionally substituted by halo, nitro, C1-6-alkyl or C1-6-haloalkyl;
• there is one or more R4, wherein each R4 is the same or different,
• R4 is one or more H, halo, C1-6-alkyl or C1-6-alkoxy
• or two R4 together with the phenyl ring to which they are attached form an oxo or dioxo bridge;
• R5 is H, C1-6-alkyl, —(CH2)m—NRiRii, aryl, or —(CH2)n—(CO)—Rb wherein Rb is NRiRii or 4 to 7 membered-heterocycloalkyl, when the dotted line does not represent a double bond,
• or is absent when the dotted line represents a double bond;
• B is halo, CN, NRiRii, C1-6-alkyl optionally substituted by CN, halo or C1-6-alkoxy, C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)NRiRii, —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, —S(O)2—NRiRii, (CRiiiRiv)n-phenyl, or (CRiiiRiv)n-5 or 6 membered heteroaryl wherein the phenyl or 5 or 6 membered heteroaryl moiety is optionally substituted by one or more substituent(s) selected from the group consisting of:
• halo, CN, NRiRii, C1-6-alkyl optionally substituted by CN or C1-6-alkoxy,
• C1-6-alkoxy, C1-6-haloalkoxy, C3-6-cycloalkyl, —C(O)O—C1-6-alkyl, —C(O)—NRiRii,
• —C(O)—C1-6-alkyl, —S(O)2—C1-6-alkyl, and —S(O)2—NRiRii;
• Ri and Rii are each independently H, C1-6-alkyl, C1-6-alkyl-NRiiiRiv, —(CO)O—C1-6-alkyl, —C(O)—NRiiiRiv, —S(O)2—C1-6-alkyl or —S(O)2—NRiiiRiv;
• Riii and Riv are each independently H or C1-6-alkyl;
• m is 1 to 6;
• and
• n is 0 to 4;
• or a pharmaceutically acceptable salt thereof.